Abstract
The kidney has numerous complex interactions with the heart, including shared risk factors (e.g., hypertension, dyslipidemia, etc.) and mutual amplification of morbidity and mortality. Both cardiovascular diseases and chronic kidney disease (CKD) may cause various alterations in cardiovascular system, metabolic homeostasis and autonomic nervous system that may facilitate the occurrence of cardiac arrhythmias. Also, pre-existent or incident cardiac arrhythmias such as atrial fibrillation (AF) may accelerate the progression of CKD.
Patients with CKD may experience various cardiac rhythm disturbances including sudden cardiac death. Contemporary management of cardiac arrhythmias includes the use of antiarrhythmic drugs (AADs), catheter ablation and cardiac implantable electronic devices (CIEDs). Importantly, AADs are not used only as the principal treatment strategy, but also as an adjunct therapy in combination with CIEDs, to facilitate their effects or to minimize inappropriate device activation in selected patients. Along with their principal antiarrhythmic effect, AADs may also induce cardiac arrhythmias and the risk for such proarrhythmic effect(s) is particularly increased in patients with reduced left ventricular systolic function or in the setting of electrolyte imbalance. Moreover, CKD itself can induce profound alterations in the pharmacokinetics and pharmacodynamics of many drugs including AADs, thus facilitating the drug accumulation and increased exposure. Hence, the use of AADs in patients with CKD may be challenging.
In this review article, we provide an overview of the characteristics of arrhythmogenesis in patients with CKD with special emphasis on the complexity of pharmacokinetics and risk for proarrhythmias when using AADs in patients with cardiac arrhythmias and CKD.
Keywords: Cardiac arrhythmias, chronic kidney disease, drug dosing, antiarrhythmic drugs, risk factors, atrial fibrillation, ventricular arrhythmias, sudden cardiac death.
Current Medicinal Chemistry
Title:Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Volume: 23 Issue: 19
Author(s): Tatjana S. Potpara, Vera Jokic, Nikolaos Dagres, Francisco Marin, Milica S. Prostran, Carina Blomstrom-Lundqvist and Gregory Y.H. Lip
Affiliation:
Keywords: Cardiac arrhythmias, chronic kidney disease, drug dosing, antiarrhythmic drugs, risk factors, atrial fibrillation, ventricular arrhythmias, sudden cardiac death.
Abstract: The kidney has numerous complex interactions with the heart, including shared risk factors (e.g., hypertension, dyslipidemia, etc.) and mutual amplification of morbidity and mortality. Both cardiovascular diseases and chronic kidney disease (CKD) may cause various alterations in cardiovascular system, metabolic homeostasis and autonomic nervous system that may facilitate the occurrence of cardiac arrhythmias. Also, pre-existent or incident cardiac arrhythmias such as atrial fibrillation (AF) may accelerate the progression of CKD.
Patients with CKD may experience various cardiac rhythm disturbances including sudden cardiac death. Contemporary management of cardiac arrhythmias includes the use of antiarrhythmic drugs (AADs), catheter ablation and cardiac implantable electronic devices (CIEDs). Importantly, AADs are not used only as the principal treatment strategy, but also as an adjunct therapy in combination with CIEDs, to facilitate their effects or to minimize inappropriate device activation in selected patients. Along with their principal antiarrhythmic effect, AADs may also induce cardiac arrhythmias and the risk for such proarrhythmic effect(s) is particularly increased in patients with reduced left ventricular systolic function or in the setting of electrolyte imbalance. Moreover, CKD itself can induce profound alterations in the pharmacokinetics and pharmacodynamics of many drugs including AADs, thus facilitating the drug accumulation and increased exposure. Hence, the use of AADs in patients with CKD may be challenging.
In this review article, we provide an overview of the characteristics of arrhythmogenesis in patients with CKD with special emphasis on the complexity of pharmacokinetics and risk for proarrhythmias when using AADs in patients with cardiac arrhythmias and CKD.
Export Options
About this article
Cite this article as:
Potpara S. Tatjana, Jokic Vera, Dagres Nikolaos, Marin Francisco, Prostran S. Milica, Blomstrom-Lundqvist Carina and Lip Y.H. Gregory, Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy, Current Medicinal Chemistry 2016; 23 (19) . https://dx.doi.org/10.2174/0929867323666160309114246
DOI https://dx.doi.org/10.2174/0929867323666160309114246 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insulin Resistance as a Therapeutic Target for Improved Endothelial Function:Metformin
Current Drug Targets - Cardiovascular & Hematological Disorders Effect of Dietary Supplementation of Black Seed (N. Sativa L.) on Lipid Profile of Patients Suffering from Diabetes
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Vascular Disease in Systemic Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Physical Activity and Insulin Resistance
Current Nutrition & Food Science Chronic Kidney Disease and Cardiovascular Disease: A Focus on Primary Care
Cardiovascular & Hematological Disorders-Drug Targets Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Inflammation-based Scores are Associated with the Prognosis of Patients with Aneurysmal Subarachnoid Hemorrhage After Neuro-intervention
Current Neurovascular Research Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
Drug Metabolism Letters An Insight Into the Anxiolytic Effects of Lignans (Phyllanthin and Hypophyllanthin) and Tannin (Corilagin) Rich Extracts of <i>Phyllanthus amarus</i> : An <i>In-Silico</i> and <i>In-vivo</i> approaches
Combinatorial Chemistry & High Throughput Screening Coronary Artery Disease and Endothelial Dysfunction: Novel Diagnostic and Therapeutic Approaches
Current Medicinal Chemistry Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Definition of Postprandial Lipaemia
Current Vascular Pharmacology Possible Underestimation by Sports Medicine of the Effects of Early Physical Exercise Practice on the Prevention of Diseases in Adulthood
Current Diabetes Reviews Winning a Won Game: Caffeine Panacea for Obesity Syndemic
Current Neuropharmacology Statins Therapy may Change a Course of Lung Fibrosis and Pulmonary Hypertension: A New Indication for Therapy or Just “Statinomania”?
Current Respiratory Medicine Reviews The Role of Statins in Preventing the Progression of Congestive Heart Failure in Patients with Metabolic Syndrome
Current Pharmaceutical Design Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued) Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis
CNS & Neurological Disorders - Drug Targets Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies
Current Alzheimer Research